Skip to Content
Merck
All Photos(3)

Documents

R3655

Sigma-Aldrich

Rubitecan

powder, ≥98% (HPLC)

Synonym(s):

9-nitrocamptothecin

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C20H15N3O6
CAS Number:
91421-42-0
Molecular Weight:
393.35
MDL number:
MFCD06656294
UNSPSC Code:
12352204
PubChem Substance ID:
329824025
NACRES:
NA.77

product name

Rubitecan,

biological source

synthetic (organic)

Assay

≥98% (HPLC)

form

powder

mp

182-186 °C

solubility

DMSO: 1 mg/mL

storage temp.

room temp

SMILES string

CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(cccc5nc34)[N+]([O-])=O)C2=O

InChI

1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1

InChI key

VHXNKPBCCMUMSW-FQEVSTJZSA-N

Biochem/physiol Actions

Topoisomerase I inhibitor. Rubitecan induces protein- linked DNA single strand breaks, blocking DNA and RNA synthesis in dividing cells. This mode of action makes rubitecan a potential chemotherapeutic agent, and it has been used with some success against refractory pancreatic cancer.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Chen et al.
Drug development and industrial pharmacy, 32(6), 719-726 (2006-08-04)
9-Nitrocamptothecin (9-NC), a newly developed camptothecin derivative, had poor solubility in any pharmaceutically acceptable solvents. One way of improving the solubility is to formulate the drug into liposomes. However, 9-NC has low affinity to lipid membranes resulting in a very
William C Zamboni et al.
Cancer chemotherapy and pharmacology, 62(3), 417-426 (2007-10-25)
We evaluated the antitumor activity of two different schedules of docetaxel and 9-nitrocamptothecin (9NC) in mice bearing human SKOV-3 ovarian carcinoma xenografts and evaluated the plasma, tissue, and tumor disposition of each agent alone and in combination. The following treatment
George R Simon et al.
Molecular cancer therapeutics, 5(8), 2130-2137 (2006-08-25)
Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I inhibitors. Here, we evaluated a sequence-specific administration of a
Ye Jiang et al.
International journal of pharmaceutics, 415(1-2), 252-258 (2011-06-08)
The aim of this study was to evaluate the safety and anti-tumor effect of 9-nitro-camptothecin/hydroxypropyl-β-cyclodextrin (9-NC/HP-β-CD) complex on tumor-bearing mice. The in vitro anti-tumor activity was tested by MTT assay. Our study revealed that the 9-NC/HP-β-CD complex showed significant anti-tumor
Howard A Burris et al.
The oncologist, 10(3), 183-190 (2005-03-29)
Additional systemic treatments for locally advanced or metastatic pancreatic cancer are needed, as current treatment options produce only modest survival benefits. Rubitecan (Orathecin; Supergen Inc., Dublin, CA, http://www.supergen.com) is an orally active camptothecin derivative with demonstrated responses in patients with
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service